Close Menu

SEC

The increased forecast is the result of continuing COVID-19 testing volumes along with recovery in its breast and skeletal business, Hologic said.

The company is developing a blood-based test to detect more than 50 cancer types across all stages and identify a tumor's tissue of origin.

The company, which went public in June, has had to deal with issues with the US DOJ, and some private insurers. Its CEO's tenure at Sequenom was also marred by a scandal.

The company recently agreed to pay millions to three major insurers under settlement agreements related to allegations over undisclosed past business practices.

The Beijing-based company offers genomics products and services, including PCR instruments and cancer sequencing, and maintains a research center in the US.

The firm said it intends to use the credit facility to support its US and European commercial paper programs and for general corporate purposes.

ArcherDx has leveraged next-generation sequencing to develop and commercialize more than 325 research-use-only products and a pan-solid tumor diagnostic test.

The Massachusetts sequencing firm has been selling technology originally developed by Helicos BioSciences and planned to increase marketing with the IPO proceeds.

Sales Stopped

The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.

The company also inked a deal with an investment bank to publicly offer from time to time up to $4.2 million of its stock.

Pages

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.